US FDA approves Biogen-Sage Therapeutics pill for postpartum depression

(Reuters) – The U.S. Food and Drug Administration on Friday approved Biogen (NASDAQ:) and Sage Therapeutics’ oral pill to treat postpartum depression (PPD (NASDAQ:)) in adults.

(This story has been corrected to say that the approval is for ‘postpartum depression,’ not ‘clinical depression’ or ‘two common forms of depression,’ in the headline and first sentence)